Cetuximab

...reported $113.5 million in revenue in 2007. Bristol-Myers generates much of its revenue through partnerships, marketing colon cancer drug Erbitux through a partnership with ImClone Systems Inc. The company also makes leukemia treatment...

In this article: Bristol-Myers, Cancer, Revenue, ImClone Systems Inc., Ixempra, Sprycel, Leukemia, Erbitux, and Breast cancer

...up 36% and leukemia drug Sprycel reached $107 million, up 30%. However, cancer drug Erbitux generated sales of $179 million in the second quarter, a decrease of 3%. Furthermore, Onglyza, co-developed with AstraZeneca plc (AZN), was...

In this article: Bristol-Myers Squibb, Revenue, Plavix, AstraZeneca plc, Bristol, Ipilimumab, LLY, Sanofi-Aventis, and Baraclude

...deal is not completed. Bristol-Myers' cancer drugs include colon cancer drug Erbitux, in partnership with ImClone, chemotherapy treatment Taxol, leukemia drug Sprycel and breast cancer treatment Ixempra. Credit Suisse Securities is...

In this article: Bristol-Myers, Cancer, All rights reserved, Ixempra, Epothilone, Sprycel, Leukemia, Erbitux, and Breast cancer

...rates in Leukemias, colon cancer, pancreatic cancer and lung cancer. KRAS mutation is predictive of response to panitumumab and cetuximab therapy in colorectal cancer. Somatic KRAS mutations are found at high rates in Leukemias, colon...

In this article: KRAS, Cancer, Panitumumab, Leukemias, Carcinoma, Phosphate, Pancreatic cancer, Nucleotide, and Lung cancer

...that compared outcomes of patients who received combination chemotherapy in conjunction with bevacizumab and cetuximab together or with cetuximab alone. The participants also received prescriptions for "supportive" drugs, such as anti-nausea...

In this article: Cancer, Dana-Farber Cancer Institute, Calgb, Anxiety, Leukemia, Bevacizumab, Antibiotic, and American Society of Clinical Oncology

The EGF system is a target for a number of new anti-cancer drugs, including Erbitux, a monoclonal antibody which binds to EGFR (the EGF receptor) and Iressa and Tarceva, the latter two being inhibitors of the EGFR-activated tyrosine kinase.

In this article: Cancer, Ovarian cancer, Topotecan, Pancreatic cancer, Multiple myeloma, Iressa, Tarceva, Lenalidomide, and Avastin

...which is effective in those who are resistant to imatinib. And last year, cetuximab (Erbitux) arrived, the first new treatment for head-and-neck cancer in 45 years. Significant advances in genetic tests that predict the outcomes of...

In this article: Cancer, National Institutes of Health, Human papillomavirus, Inflation, Lapatinib, and Dasatinib